# IDEAYA Biosciences, Inc.: financial statements, quarterly

IDYA · Nasdaq · CIK 1676725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/idya.md) · [Financials](/companies/idya/financials.md) · [Filings](/companies/idya/filings.md) · [Insiders](/companies/idya/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/idya/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.0](/filings/0000950170-24-120675.md) | [3.9 d](/filings/0001193125-26-054533.md) | [0.0](/filings/0000950170-24-054466.md) | [0.0](/filings/0000950170-24-091823.md) | [0.0](/filings/0000950170-24-120675.md) | [7.0 d](/filings/0001193125-26-054533.md) | not reported | not reported | [208](/filings/0001193125-25-264632.md) | [10.9 d](/filings/0001193125-26-054533.md) | [6.6](/filings/0001193125-26-206357.md) | [8.9](/filings/0001193125-26-332774.md) |
| Research and development | $m | [33.7](/filings/0000950170-24-120675.md) | [38.8 d](/filings/0001193125-26-054533.md) | [42.8](/filings/0000950170-25-064438.md) | [54.5](/filings/0000950170-25-102967.md) | [57.2](/filings/0001193125-25-264632.md) | [140 d](/filings/0001193125-26-054533.md) | [70.9](/filings/0001193125-26-206357.md) | [74.2](/filings/0001193125-26-332774.md) | [83.0](/filings/0001193125-25-264632.md) | [86.6](/filings/0001193125-26-206357.md) | [95.7](/filings/0001193125-26-332774.md) | [109](/filings/0001193125-26-332774.md) |
| Operating income | $m | [(33.5)](/filings/0000950170-24-120675.md) | [(41.9) d](/filings/0001193125-26-054533.md) | [(51.0)](/filings/0000950170-25-064438.md) | [(64.9)](/filings/0000950170-25-102967.md) | [(66.9)](/filings/0001193125-25-264632.md) | [(144) d](/filings/0001193125-26-054533.md) | [(84.4)](/filings/0001193125-26-206357.md) | [(88.8)](/filings/0001193125-26-332774.md) | [108](/filings/0001193125-25-264632.md) | [(94.6) d](/filings/0001193125-26-054533.md) | [(109)](/filings/0001193125-26-206357.md) | [(122)](/filings/0001193125-26-332774.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-120675.md) | [0.0 d](/filings/0001193125-26-054533.md) | [0.0](/filings/0000950170-25-064438.md) | [0.0](/filings/0000950170-25-102967.md) | [0.0](/filings/0000950170-24-120675.md) | [0.0 d](/filings/0001193125-26-054533.md) | [0.0](/filings/0001193125-26-206357.md) | [0.0](/filings/0000950170-25-102967.md) | [0.0 d](/filings/0001193125-25-264632.md) | [0.0 d](/filings/0001193125-26-054533.md) | [0.0](/filings/0001193125-26-206357.md) | [0.0 d](/filings/0001193125-26-332774.md) |
| Net income | $m | [(27.4)](/filings/0000950170-24-120675.md) | [(34.0) d](/filings/0001193125-26-054533.md) | [(39.6)](/filings/0000950170-25-064438.md) | [(52.8)](/filings/0000950170-25-102967.md) | [(51.8)](/filings/0001193125-25-264632.md) | [(130) d](/filings/0001193125-26-054533.md) | [(72.2)](/filings/0001193125-26-206357.md) | [(77.5)](/filings/0001193125-26-332774.md) | [119](/filings/0001193125-25-264632.md) | [(83.3) d](/filings/0001193125-26-054533.md) | [(98.5)](/filings/0001193125-26-206357.md) | [(112)](/filings/0001193125-26-332774.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-24-120675.md) | not reported | [(0.53)](/filings/0000950170-25-064438.md) | [(0.68)](/filings/0000950170-25-102967.md) | [(0.60)](/filings/0001193125-25-264632.md) | not reported | [(0.82)](/filings/0001193125-26-206357.md) | [(0.88)](/filings/0001193125-26-332774.md) | [1.33](/filings/0001193125-25-264632.md) | not reported | [(1.11)](/filings/0001193125-26-206357.md) | [(1.22)](/filings/0001193125-26-332774.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0000950170-24-120675.md) | not reported | [(0.53)](/filings/0000950170-25-064438.md) | [(0.68)](/filings/0000950170-25-102967.md) | [(0.60)](/filings/0001193125-25-264632.md) | not reported | [(0.82)](/filings/0001193125-26-206357.md) | [(0.88)](/filings/0001193125-26-332774.md) | [1.35](/filings/0001193125-25-264632.md) | not reported | [(1.11)](/filings/0001193125-26-206357.md) | [(1.22)](/filings/0001193125-26-332774.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [152](/filings/0000950170-24-120675.md) | [157](/filings/0001193125-26-054533.md) | [108](/filings/0000950170-25-064438.md) | [183](/filings/0000950170-25-102967.md) | [400](/filings/0001193125-25-264632.md) | [84.4](/filings/0001193125-26-054533.md) | [130](/filings/0001193125-26-206357.md) | [115](/filings/0001193125-26-332774.md) | [299](/filings/0001193125-25-264632.md) | [113](/filings/0001193125-26-332774.md) | [158](/filings/0001193125-26-206357.md) | [273](/filings/0001193125-26-332774.md) |
| Current assets | $m | [482](/filings/0000950170-23-060206.md) | [533](/filings/0000950170-25-022183.md) | [709](/filings/0000950170-24-054466.md) | [713](/filings/0000950170-24-091823.md) | [932](/filings/0000950170-24-120675.md) | [690](/filings/0001193125-26-054533.md) | [708](/filings/0000950170-25-064438.md) | [686](/filings/0000950170-25-102967.md) | [803](/filings/0001193125-25-264632.md) | [667](/filings/0001193125-26-332774.md) | [696](/filings/0001193125-26-206357.md) | [864](/filings/0001193125-26-332774.md) |
| Total assets | $m | [533](/filings/0000950170-23-060206.md) | [649](/filings/0000950170-25-022183.md) | [962](/filings/0000950170-24-054466.md) | [974](/filings/0000950170-24-091823.md) | [1,240](/filings/0000950170-24-120675.md) | [1,124](/filings/0001193125-26-054533.md) | [1,101](/filings/0000950170-25-064438.md) | [1,041](/filings/0000950170-25-102967.md) | [1,185](/filings/0001193125-25-264632.md) | [1,109](/filings/0001193125-26-332774.md) | [1,030](/filings/0001193125-26-206357.md) | [1,310](/filings/0001193125-26-332774.md) |
| Current liabilities | $m | [24.9](/filings/0000950170-23-060206.md) | [27.1](/filings/0000950170-25-022183.md) | [25.0](/filings/0000950170-24-054466.md) | [40.7](/filings/0000950170-24-091823.md) | [40.7](/filings/0000950170-24-120675.md) | [46.1](/filings/0001193125-26-054533.md) | [50.8](/filings/0000950170-25-064438.md) | [55.3](/filings/0000950170-25-102967.md) | [64.5](/filings/0001193125-25-264632.md) | [58.8](/filings/0001193125-26-332774.md) | [64.8](/filings/0001193125-26-206357.md) | [82.7](/filings/0001193125-26-332774.md) |
| Total liabilities | $m | [24.9](/filings/0000950170-23-060206.md) | [28.2](/filings/0000950170-25-022183.md) | [26.2](/filings/0000950170-24-054466.md) | [42.0](/filings/0000950170-24-091823.md) | [59.5](/filings/0000950170-24-120675.md) | [64.9](/filings/0001193125-26-054533.md) | [76.5](/filings/0000950170-25-064438.md) | [81.6](/filings/0000950170-25-102967.md) | [93.1](/filings/0001193125-25-264632.md) | [86.4](/filings/0001193125-26-332774.md) | [93.1](/filings/0001193125-26-206357.md) | [111](/filings/0001193125-26-332774.md) |
| Shareholders' equity | $m | [508](/filings/0000950170-24-120675.md) | [621](/filings/0001193125-26-054533.md) | [935](/filings/0000950170-25-102967.md) | [932](/filings/0001193125-25-264632.md) | [1,180](/filings/0001193125-25-264632.md) | [1,059](/filings/0001193125-26-332774.md) | [1,024](/filings/0001193125-26-332774.md) | [960](/filings/0001193125-26-332774.md) | [1,092](/filings/0001193125-25-264632.md) | [1,023](/filings/0001193125-26-332774.md) | [937](/filings/0001193125-26-332774.md) | [1,199](/filings/0001193125-26-332774.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(30.2) d](/filings/0000950170-24-120675.md) | [(23.7) d](/filings/0001193125-26-054533.md) | [(43.8)](/filings/0000950170-25-064438.md) | [(32.9) d](/filings/0000950170-25-102967.md) | [(49.2) d](/filings/0001193125-25-264632.md) | [(122) d](/filings/0001193125-26-054533.md) | [(60.3)](/filings/0001193125-26-206357.md) | [(62.5) d](/filings/0001193125-26-332774.md) | [142 d](/filings/0001193125-25-264632.md) | [(90.5) d](/filings/0001193125-26-054533.md) | [(75.2)](/filings/0001193125-26-206357.md) | [(88.2) d](/filings/0001193125-26-332774.md) |
| Capital expenditure | $m | [0.6 d](/filings/0000950170-24-120675.md) | [0.8 d](/filings/0001193125-26-054533.md) | [1.3](/filings/0000950170-25-064438.md) | [1.0 d](/filings/0000950170-25-102967.md) | [0.5 d](/filings/0001193125-25-264632.md) | [1.1 d](/filings/0001193125-26-054533.md) | [1.3](/filings/0001193125-26-206357.md) | [0.7 d](/filings/0001193125-26-332774.md) | [0.0 d](/filings/0001193125-25-264632.md) | [0.3 d](/filings/0001193125-26-054533.md) | [1.0](/filings/0001193125-26-206357.md) | [0.9 d](/filings/0001193125-26-332774.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.1](/filings/0000950170-23-060206.md) | [48.4](/filings/0000950170-24-054466.md) | [56.3](/filings/0000950170-24-091823.md) | [60.0](/filings/0000950170-24-120675.md) | [75.1](/filings/0000950170-25-064438.md) | [78.0](/filings/0000950170-25-102967.md) | [86.2](/filings/0001193125-25-264632.md) | [88.4](/filings/0001193125-26-206357.md) | [88.5](/filings/0001193125-26-332774.md) | [89.7](/filings/0001193125-25-264632.md) | [88.7](/filings/0001193125-26-206357.md) | [92.1](/filings/0001193125-26-332774.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,489,484 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332774.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.